Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | YAP1 | P46937 | 1/20 | 0.55 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | GPR183 | P32249 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7356750 | 0.89 | USP2 (0.78) | USP2TSHRYAP1TEAD4GAA | |
| SCHEMBL4815957 | 0.89 | USP2 (0.78) | USP2TSHRYAP1TEAD4GAA | |
| SCHEMBL5949547 | 0.82 | TSHR (0.61) | USP2TSHRYAP1TEAD4GAA | |
| SCHEMBL5949555 | 0.82 | TSHR (0.61) | USP2TSHRYAP1TEAD4GAA | |
| SCHEMBL21800682 | 0.80 | GAA (0.69) | USP2YAP1TEAD4GAAALDH1A1 | |
| SCHEMBL21800599 | 0.79 | TSHR (0.57) | USP2TSHRYAP1TEAD4GAA | |
| SCHEMBL10273453 | 0.79 | ALDH1A1 (0.52) | USP2TSHRYAP1TEAD4GAA | |
| SCHEMBL21800713 | 0.78 | EPHX2 (0.55) | USP2TSHRYAP1TEAD4KMT2A | |
| SCHEMBL5368158 | 0.77 | RAB9A (0.69) | GAAALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL27525127 | 0.77 | RAB9A (0.69) | GAAALDH1A1KMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342020-B2 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| EP-1109787-B1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | ASTRAZENECA AB (SE) | 2006-05-17 | — | — | EP | disclosed |
| US-20040171641-A1 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | US | disclosed |
| US-6734184-B1 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| EP-1109787-A1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | AstraZeneca AB (SE) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012478-A1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171641-A1 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | MMP13, MMP25, MMP3 | USP2 1877/4885TSHR 2604/4885YAP1 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.